文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

联合生物标志物预测疑似脓毒症危重患者的急性死亡率

Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在疑似细菌性脓毒症的ICU患者中,血清淀粉样P物质与组织型纤溶酶原激活物联合预测14天和全因住院死亡率的AUC分别>0.76和0.74。

该队列研究纳入139例符合至少2项全身炎症反应综合征标准并接受新广谱抗菌治疗的ICU患者,在疑似脓毒症起始及24、48、72小时检测9种生物标志物。14天死亡率为12.9%,总住院死亡率为29.5%。血清淀粉样P物质在14天死亡组4个时间点均显著降低,组织型纤溶酶原激活物在3个时间点显著升高,总住院死亡率呈现相同模式。血清淀粉样P物质和组织型纤溶酶原激活物个体预测性能最佳,包含二者的联合标志物预测14天死亡率的AUC>0.76、总死亡率的AUC>0.74。

要点

  • 在疑似脓毒症ICU患者中,血清淀粉样P物质在14天死亡组4个时间点均显著降低,组织型纤溶酶原激活物在3个时间点显著升高。
  • 血清淀粉样P物质和组织型纤溶酶原激活物个体预测性能最佳,联合二者预测14天死亡率AUC>0.76、总住院死亡率AUC>0.74。
  • 该队列14天死亡率为12.9%,总住院死亡率为29.5%。
  • 纳入标准为符合至少2项全身炎症反应综合征标准并接受新广谱抗菌治疗。
  • 生物标志物在疑似脓毒症起始及24、48、72小时共4个时间点检测。

适用人群与场景

  • 纳入标准:符合至少2项全身炎症反应综合征标准并接受新广谱抗菌治疗的成人ICU患者,共139例。
  • 场景:学术医疗中心的内科和外科ICU。

诊断标准与关键阈值

  • 全身炎症反应综合征标准:符合至少2项。
  • 疑似细菌性脓毒症:临床怀疑并接受新广谱抗菌治疗。

研究设计与关键结果

  • 研究类型:队列研究;样本量139例;场所为学术医疗中心的内科和外科ICU。
  • 干预:在疑似脓毒症起始及24、48、72小时检测9种生物标志物(α-2巨球蛋白、C反应蛋白、铁蛋白、纤维蛋白原、结合珠蛋白、降钙素原、血清淀粉样A、血清淀粉样P、组织型纤溶酶原激活物)。
  • 主要终点:14天死亡率为12.9%,总住院死亡率为29.5%。
  • 血清淀粉样P物质在14天死亡组4个时间点均显著降低,组织型纤溶酶原激活物在3个时间点显著升高(Wilcoxon p≤0.046);总住院死亡率呈现相同模式。
  • 血清淀粉样P物质和组织型纤溶酶原激活物个体预测性能最佳;包含二者的联合标志物预测14天死亡率AUC>0.76、总住院死亡率AUC>0.74。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在疑似细菌性脓毒症的ICU患者中,联合检测血清淀粉样P物质和组织型纤溶酶原激活物可能有助于预测14天和总住院死亡风险。
  • 血清淀粉样P物质降低和组织型纤溶酶原激活物升高与死亡风险增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Sepsis is associated with high early and total in-hospital mortality. Despite recent revisions in the diagnostic criteria for sepsis that sought to improve predictive validity for mortality, it remains difficult to identify patients at greatest risk of death. We compared the utility of nine biomarkers to predict mortality in subjects with clinically suspected bacterial sepsis.

DESIGN: Cohort study.

SETTING: The medical and surgical ICUs at an academic medical center.

SUBJECTS: We enrolled 139 subjects who met two or more systemic inflammatory response syndrome (systemic inflammatory response syndrome) criteria and received new broad-spectrum antibacterial therapy.

INTERVENTIONS: We assayed nine biomarkers (α-2 macroglobulin, C-reactive protein, ferritin, fibrinogen, haptoglobin, procalcitonin, serum amyloid A, serum amyloid P, and tissue plasminogen activator) at onset of suspected sepsis and 24, 48, and 72 hours thereafter. We compared biomarkers between groups based on both 14-day and total in-hospital mortality and evaluated the predictive validity of single and paired biomarkers via area under the receiver operating characteristic curve.

MEASUREMENTS AND MAIN RESULTS: Fourteen-day mortality was 12.9%, and total in-hospital mortality was 29.5%. Serum amyloid P was significantly lower (4/4 timepoints) and tissue plasminogen activator significantly higher (3/4 timepoints) in the 14-day mortality group, and the same pattern held for total in-hospital mortality (Wilcoxon p ≤ 0.046 for all timepoints). Serum amyloid P and tissue plasminogen activator demonstrated the best individual predictive performance for mortality, and combinations of biomarkers including serum amyloid P and tissue plasminogen activator achieved greater predictive performance (area under the receiver operating characteristic curve > 0.76 for 14-d and 0.74 for total mortality).

CONCLUSIONS: Combined biomarkers predict risk for 14-day and total mortality among subjects with suspected sepsis. Serum amyloid P and tissue plasminogen activator demonstrated the best discriminatory ability in this cohort.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kelly BJ, Lautenbach E, Nachamkin I, et al. Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis. Crit Care Med. 2018. PMID: 29912095. doi:10.1097/CCM.0000000000003137

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。